Amryt Pharma Share Discussion Threads

[pottermagic2310] 05/5/2016 15:21

I'm simply considering the forward-looking prospects of the Company I now find myself invested in and the potential for its current & future Products. All we can do is stay invested if one believes in the Business and its opportunities OR sell if you don't think it has any hope of doing any profitable Business.
I'm in for the year, for now... a stable share price permitting

[papillon] 05/5/2016 13:33

Unfortunately, JP, it's not the BoD who are currently shatting on PI's it's the PI's who are currently selling who are shatting on other PI's, like you. It's the sellers and the absence of buyers, not the BoD, who are currently driving down the sp, not the BoD. I'm fairly certain that if the BoD could support the share price by issuing a positive RNS they would. However we had the good news with the RTO last month. I very much doubt if there is any good news to be issued after such a short time period.

Unfortunately you're an ars*hole, JP. You have said you would sell your FAST shares when the share price was over 3p. You had the chance to sell when FAST returned from suspension on the 31st March, but didn't take the opportunity. More fool you. Stop bleating you ars*hole. You had your chance, but didn't take it!

[barnes4] 05/5/2016 10:33

Dont worry JP

[jacksonpollack] 05/5/2016 10:26

Patience whilst the share price slips from 24p into the 18p's. Pi's shat on again.

[alphabravo321] 04/5/2016 18:02

Patience Patience Patience

[currypasty] 04/5/2016 17:48

just waiting

[jacksonpollack] 04/5/2016 17:21

deckav. Yes, small pi's shafted as per usual.

[bigwavedave] 04/5/2016 11:27

I'm still in. Still very much interested, although under water with this one. Must confess I thought the share price would have improved my now ie at least above the 3p/24p mark. But I guess it will have to be later rather than sooner.

[cpap man] 04/5/2016 11:17

Amryt Pharma (LON:AMYT- Market Cap £40 Million)

Amryt Pharma (completed its IPO by the successful RTO of Fastnet Equity in April 2016) is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Amryt's lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan as a new treatment for Epidermolysis Bullosa - a hereditary skin disorder and very large unmet market opportunity.

Amryt CEO Joe Wiley will be at the forum to outline the company's plans as it move forwards.

[deckav] 04/5/2016 09:59

Very quite here. Any comments on the slide to 19 ?

[papillon] 03/5/2016 20:26

No one appears to be interested in AMYT judging by this quiet message board. It needs a good news RNS to re-ignite investor interest. Will that good news RNS be released anytime soon? No idea! Fingers crossed.

[papillon] 01/5/2016 21:27

Amryt Pharmaceuticals is worth a closer look

By Gary Newman | Sunday 1 May 2016


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


As usual I had a great day at the UK Investor Show, especially listening to many of the informative speakers on the main stage.

When it came to the companies exhibiting, to be honest there are many of them which I wouldn’t dream of putting my money into – either because I view them as poorly run or vastly over-valued at their current share prices.

But there were also some that look to have good potential for the future, as well as offering value, and are definitely on my watch list, and amongst them was recently listed Amryt Pharmaceuticals (AMYT) which completed a reverse takeover into Fastnet Equity and was admitted to trading a couple of weeks ago.

I previously covered this company as a buy at 2.9p one weekend back in late February, but it was then suspended before open on the Monday morning when news of the deal was confirmed, and you can now get in even cheaper as the opening day price of 24p (equivalent to 3p prior to the deal) has subsequently dropped to under 20p to buy.

It is still early days and like any similar stage pharmaceutical company it does carry a fair amount of risk, but unlike many of the AIM listed ones it does at least have a product, Episalvan, that is already approved in the EU, Norway and Iceland, and also has further potential for development to treat other diseases.

Amryt has a very short history as it was only formed in August of last year, but that came about via the acquisitions of German bio-tech Birken AG and Swiss pharmaceuticals company Sompharmaceuticals SA. It also has a team behind it that have a good track record in the industry, with chairman Harry Stratford having previously built two successful listed pharma companies (including Shire which is now FTSE100 listed), and CEO Joe Wiley and CFO/COO Rory Nealon who have years of experience in life sciences.

Its licenced product Episalvan is used to treat partial-thickness wounds in adults, but the company is looking to extend that to epidermolysis bullosa, which commonly occurs in children, and is expecting to begin phase three trials in the second half of this year. The company currently has orphan status in both the US and EU for this potential EB treatment, meaning that not only will it get tax breaks but also an exclusivity period to develop a cure for this condition.

The only downside with that is that orphan drugs tend to be less profitable than those that cure common illnesses, but can still be very lucrative and the global EB market is estimated at $1.5 billion per annum, so the company won’t even need a big slice of that to succeed.

Amryt also has the Imlan brand (developed by Birken) which is on sale and is used by people suffering from dry skin and other dermatitis conditions.

There are also a couple of other drugs, but they are yet to undergo clinical trials and are too early a stage to really be that relevant at the moment, although that could well change in the future.

In terms of the financials it is very hard to get a real grip on these as there isn’t a lot to go on by way of figures, other than that the company raised a gross amount of £10 million at 24p when it listed in April, and prior to that it also had close to £10 million in the bank. The total amount paid for the takeover of Amryt was just under £30 million in shares and was settled by the issue of 123 million shares (circa 59%) in the new company, with those who originally sold Birken receiving 30 million of those, and 12 million going to former Som owners.

Since relisting it should have paid Birken €10 million as a milestone payment for the Episalvan EU approval, with potentially a further €40 million to pay in the future, plus royalties on this product of 6-9% of sales for a ten year period.

For a company of this size there is a relatively small freefloat, with over 62% of shares not in public hands, and the Software AG-Stiftung fund owning 20.9%, and previously having funded Birken to the tune of around €54 million to develop its products.

There is too much to go into every detail, so I would suggest that anyone interested in investing reads the admission document before doing so, and also realises that this does still have risks attached if it is going to justify its current market cap of £42 million.

But I think the current share price, or possibly even slightly lower if you get he chance, offers a good buying opportunity as I think many people piled into this one expecting fireworks overnight.

But typically of many PIs, when that didn’t happen they have gradually got bored and sold to chase riches elsewhere, and that has dragged the share price down to where it is. That unfortunately is also one of the disadvantages of a small freefloat as it doesn’t take a lot of selling to have a disproportionate affect on the share price, but that also works the other way at times when the shares are in high demand, such as after good news.

So for me overall this is a speculative buy at these levels, especially given how far along the road it is with its products compared to many similar sized pharmas. Just be aware that it will need to raise further funding in the future, although that might not need to be via equity issue given previous funding from the biggest shareholder.
- See more at:

[currypasty] 29/4/2016 10:51

actually the quote from the sunday paper (link in header) says

"They will get Amryt shares valued at a 30% premium to their investment, ahead of its flotation on London’s AIM and Dublin’s ESM on April 19"

so working it that way round, they may have paid 18.5p (18.5 x 1.3 = 24p placing price)


PI's can buy in the market now at just over 19!

[currypasty] 29/4/2016 10:43

the 30% discount means they are sat at about 17p. If they sold on re-list, then yes they made a good turn. Not so good selling now at 19p though, and no volume to be able to sell anyway, so perhaps they are holding?

[jacksonpollack] 28/4/2016 17:00

joesoap3. Exactly. Total pistake. Those big hitters on the 30% discount will have made a killing no doubt.

[joesoap3] 28/4/2016 15:33

Based on the latest trade at 15.26, the price is 2.393p in old Fastnet share price. far cry from the figures put out at suspension forecasting the price after the return from suspension

[jacksonpollack] 27/4/2016 20:20

Your damn right friel made a good call. Certainly a good call for him. A company he is involved in buys into another company he is involved in using money from another company he is involved in resulting in another company he is involved in, lol.

[papillon] 27/4/2016 19:04

They were worth NOTHING when they were suspended, JacksonPillock!! Only a cretin would think a suspended share has any value. You can't sell a suspended share!!!!!!

Look at FAST's peer group PVR, LOGP (& SEA). All skint and all suspended and maybe shareholders in all 3 companies have lost all of the money they invested. At least FAST/AMYT is alive and kicking and has a future away from O&G. Friel made a good call to get FAST out of O&G.

[jacksonpollack] 27/4/2016 17:02

Should have stayed suspended. At least my shares were worth more.

[bigwavedave] 26/4/2016 10:47

I'd like to. But no can do, unfortunately.

[jacksonpollack] 26/4/2016 10:39

No. Just another champagne and prawn sandwich doo. Waste of time and money

[currypasty] 26/4/2016 10:36

anyone going ?